SLC5A2 and hydrops fetalis: Empagliflozin or dapagliflozin SGLT2 inhibition is recommended as an adjunct to conventional medical care for HFrEF, owing to its significant advantages in decreasing all‐cause and cardiovascular mortality, HF hospitalizations, and severe adverse renal outcomes.36, 37, 38